Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

29.96 +11.02 (+58.13%)
Streaming Delayed Price Updated: 11:11 AM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vera Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Why Shares of Vera Therapeutics Are Soaring Monday
The company, which specializes in autoimmune disorders affecting the kidney, benefited from a renewed interest in kidney therapies. 
Via The Motley Fool
US Stocks Open Higher; Nasdaq Rises Over 50 Points
U.S. stocks traded higher this morning, with Nasdaq Composite gaining over 50 points on Monday. Following the market opening Monday, the Dow traded up 0.21% to 33,948.78 while the NASDAQ rose 0.47% to... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
7 Stocks That Wall Street Analysts Are Loving in June
Sometimes, it’s better to get your ideas from the experts. Thus, if you lack time, these top analyst recommend stocks could be enticing. 
Via InvestorPlace
Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Recap: Vera Therapeutics Q1 Earnings
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Vera Therapeutics: Here's What You Need To Know
Via Benzinga
Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs
From Vera Therapeutics
Via GlobeNewswire
Why Vera Therapeutics Stock Bolted Higher This Week
Vera's stock gained a noteworthy 49% this week. 
Via The Motley Fool
$12M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed mixed on Monday, there were a few notable insider trades. 
Via Benzinga
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
From Vera Therapeutics
Via GlobeNewswire
$12M Bet On Vera Therapeutics? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! 
Via InvestorPlace
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Releases Interim Analysis Of Rare Kidney Disease Drug, Deprioritizes Certain Phase 3 Programs
Vera Therapeutics Inc (NASDAQ: VERA) has announced results from a prespecified per-protocol (PP) analysis of the Phase 2b ORIGIN trial of atacicept in IgA nephropathy (IgAN) patients. 
Via Benzinga
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)
From Vera Therapeutics
Via GlobeNewswire
5 Cheapest Health Care Stocks You Should Think About
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vera Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Top 5 Health Care Stocks That May Surge
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 63 companies set new 52-week lows. 
Via Benzinga
Dow Gains 150 Points After Fed Minutes
U.S. stocks traded higher toward the end of trading, following the release of minutes from the FOMC meeting. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.